QuidelOrtho Corporation
NASDAQ:QDELMedical - Instruments & Supplies
+$0.09 today
- Market cap
- $656.62M
- Beta
- 0.76
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$17.76
Volume 2.13M
Average 2.35M
QDEL Total Debt
Short-term and long-term borrowings combined.
QuidelOrtho CorporationNASDAQ: QDEL
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 6.7% from a year ago
Total debt stood at $2.87B at the end of Q1 FY2026, up 6.7% from a year earlier and up 1.4% from the prior quarter. Over 3 fiscal years it compounded at -0.2% a year.
Context
- Total debt amounted to 51.1% of total assets at the end of Q1 FY2026, up 9.4 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +6.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 2.83B USD
- Year-over-year change
- +5.7%
- 4-year CAGR
- +112.4%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 2.83B | +5.7% |
| FY2024 | 2024-12-29 | 2.68B | +2.6% |
| FY2023 | 2023-12-31 | 2.61B | -8.2% |
| FY2022 | 2023-01-01 | 2.85B | +1945.3% |
| FY2021 | 2021-12-31 | 139.3M | — |
Total Debt vs competitors
How QDEL compares with its peers on the latest reported figures
- QDEL's Mar 2026 total debt of $2.87B is the 4th highest of the 9 companies compared; the peer median is $800.31M.
- Its year-over-year change of +6.7% is the 4th highest of 8, against a peer median of -1.0%.
- Total debt amounts to 51.1% of total assets for QDEL, versus a peer median of 24.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $41.37B | +15.9% | +3.0% | 36.2% | |
| Sep 2026 | $6.29B | -1.5% | +13.6% | 36.5% | |
| Jul 2026 | $3.34B | -1.0% | -8.5% | 27.7% | |
| Mar 2026 | $2.87B | +6.7% | -0.2% | 51.1% | |
| Jun 2026 | $1.2B | -14.4% | +3.3% | 11.7% | |
| Mar 2026 | $396.93M | -19.5% | +12.4% | 21.4% | |
| Dec 2025 | $137.98M | +36.9% | +24.1% | 131.2% | |
| Mar 2026 | $40.47M | +184.9% | +1.7% | 10.7% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | Dec 2025 | $0 | — | — | 0.0% |
| Peer median (excluding QDEL) | $800.31M | -1.0% | +3.3% | 24.6% | |
Competitors are the stored peer set for QDEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Jan 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 802.8M | 292.9M | 118.9M | 98.3M | 169.8M |
| Short-term Investments | 25.7M | 52.1M | 48.4M | 0 | 32.4M |
| Net Receivables | 393.8M | 586.4M | 488.4M | 451.3M | 417M |
| Inventory | 198.8M | 524.1M | 577.8M | 533.7M | 577.6M |
| Other Current Assets | 4.6M | 22.9M | 10M | 58.3M | 0 |
| Total Current Assets | 1.44B | 1.58B | 1.31B | 1.22B | 1.45B |
| Property, Plant & Equipment (Net) | 476.8M | 1.52B | 1.61B | 1.55B | 1.51B |
| Goodwill | 337M | 2.48B | 2.49B | 649.5M | 0 |
| Intangible Assets | 98.7M | 3.12B | 2.93B | 2.74B | 2.56B |
| Long-term Investments | 37.9M | 21M | 7.4M | 21.7M | 0 |
| Tax Assets | 20.1M | 16.4M | 25.9M | 0 | 0 |
| Other Non-current Assets | 19.6M | 122.7M | 179.6M | 249M | 244.4M |
| Total Non-current Assets | 990.1M | 7.28B | 7.25B | 5.2B | 4.32B |
| Total Assets | 2.43B | 8.86B | 8.56B | 6.42B | 5.77B |
| Account Payables | 101.5M | 283.3M | 294.8M | 246M | 279.4M |
| Short-term Debt | 300K | 207.5M | 139.8M | 341.8M | 178.3M |
| Tax Payables | 77.1M | 51.6M | 29M | 5.4M | 11.5M |
| Deferred Revenue | 1.9M | 76.4M | 36.8M | 33.5M | 37.8M |
| Other Current Liabilities | 65.5M | 156.4M | 127.8M | 96.8M | 164.3M |
| Total Current Liabilities | 323.5M | 1.01B | 833.8M | 998.8M | 966.1M |
| Long-term Debt | 400K | 2.43B | 2.27B | 2.14B | 2.47B |
| Deferred Tax Liabilities | 0 | 213.2M | 192.2M | 76.5M | 90M |
| Deferred Revenue (Non-current) | 0 | 9.4M | 0 | 17.3M | 0 |
| Other Non-current Liabilities | 48.5M | 74.4M | 83.6M | 38M | 166.4M |
| Total Non-current Liabilities | 177.5M | 2.91B | 2.72B | 2.44B | 2.88B |
| Total Liabilities | 501M | 3.92B | 3.56B | 3.44B | 3.85B |
| Common Stock | 0 | 0 | 100K | 100K | 100K |
| Retained Earnings | 1.65B | 2.2B | 2.19B | 135.8M | (996M) |
| Accumulated OCI | 400K | (67.6M) | (30M) | (36.2M) | (15.4M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.93B | 4.93B | 5.01B | 2.98B | 1.92B |
| Total Debt | 139.3M | 2.85B | 2.61B | 2.68B | 2.83B |
| Net Debt | (663.5M) | 2.56B | 2.5B | 2.58B | 2.66B |
QuidelOrtho Corporation
NASDAQ:QDEL
Intrinsic Alpha fair value
Locked
Current Price
$9.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.